AstraZeneca shares fell 7% after news emerged that it is in talks to buy US rival Bristol Myers Squibb, potentially forming a pharmaceutical group valued near $400 billion. This move would significantly expand AstraZeneca's presence in the US market and mark a strategic shift for CEO Pascal Soriot, who previously rejected a Pfizer takeover. Bristol Myers Squibb recently reported strong quarterly results and raised its annual outlook, adding momentum to the potential deal. AstraZeneca aims to hit $80 billion in annual sales by 2030 despite recent drug development setbacks.
Alibaba unveiled its new AI model, Qwen3.8-Max, built on 2.4 trillion parameters, claiming performance comparable to top global AI systems. The model outperformed competitors in benchmarks and demonstrated autonomous coding by completing a software p...
AstraZeneca is in talks with US rival Bristol Myers Squibb about a potential merger that could form one of the world's largest pharmaceutical companies valued at nearly $400 billion. The discussions have been ongoing for several months and may conclu...
UK pharmaceutical company AstraZeneca is in talks to merge with US rival Bristol Myers Squibb, potentially forming a combined entity valued at around $400 billion. The merger would be one of the largest in history, combining AstraZeneca's global reac...
AstraZeneca disclosed that its Phase-3 trial for Wainua, a treatment for amyloid cardiomyopathy, failed to meet its primary endpoint, causing its stock to drop 5.7% on July 9, 2026. Following this, Pomerantz LLP announced an investigation into whethe...
